• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

二聚体拟肽通过二聚化刺突蛋白来预防 SARS-CoV-2 感染。

A dimeric proteomimetic prevents SARS-CoV-2 infection by dimerizing the spike protein.

机构信息

Molecular Biophysics Unit (MBU), Indian Institute of Science, Bangalore, India.

Virology Unit, Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Chandigarh, India.

出版信息

Nat Chem Biol. 2022 Oct;18(10):1046-1055. doi: 10.1038/s41589-022-01060-0. Epub 2022 Jun 2.

DOI:10.1038/s41589-022-01060-0
PMID:35654847
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9512702/
Abstract

Protein tertiary structure mimetics are valuable tools to target large protein-protein interaction interfaces. Here, we demonstrate a strategy for designing dimeric helix-hairpin motifs from a previously reported three-helix-bundle miniprotein that targets the receptor-binding domain (RBD) of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Through truncation of the third helix and optimization of the interhelical loop residues of the miniprotein, we developed a thermostable dimeric helix-hairpin. The dimeric four-helix bundle competes with the human angiotensin-converting enzyme 2 (ACE2) in binding to RBD with 2:2 stoichiometry. Cryogenic-electron microscopy revealed the formation of dimeric spike ectodomain trimer by the four-helix bundle, where all the three RBDs from either spike protein are attached head-to-head in an open conformation, revealing a novel mechanism for virus neutralization. The proteomimetic protects hamsters from high dose viral challenge with replicative SARS-CoV-2 viruses, demonstrating the promise of this class of peptides that inhibit protein-protein interaction through target dimerization.

摘要

蛋白质三级结构模拟物是靶向大型蛋白质-蛋白质相互作用界面的有价值的工具。在这里,我们展示了一种从先前报道的靶向严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 受体结合域 (RBD) 的三螺旋束微蛋白设计二聚体螺旋发夹基序的策略。通过截短第三个螺旋和优化微蛋白的螺旋间环残基,我们开发了一种热稳定的二聚体螺旋发夹。二聚体四螺旋束以 2:2 化学计量与人类血管紧张素转换酶 2 (ACE2) 竞争与 RBD 的结合。低温电子显微镜显示四螺旋束形成二聚体刺突外域三聚体,其中来自刺突蛋白的所有三个 RBD 以开放构象头对头附着,揭示了一种新的病毒中和机制。该蛋白模拟物可保护仓鼠免受高剂量复制性 SARS-CoV-2 病毒的挑战,证明了通过靶向二聚化抑制蛋白质-蛋白质相互作用的这类肽的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/21fbc00f24bc/41589_2022_1060_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/7dcc8eede344/41589_2022_1060_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/ffc9cffe9653/41589_2022_1060_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/224aa7a56027/41589_2022_1060_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/014d9bcd137f/41589_2022_1060_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/c51c5945971b/41589_2022_1060_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/481daa279206/41589_2022_1060_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/9576f3649c88/41589_2022_1060_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/738df6db5a0d/41589_2022_1060_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/cd4d38b0aa69/41589_2022_1060_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/50e5692079af/41589_2022_1060_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/72c432ada69e/41589_2022_1060_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/899ead596b76/41589_2022_1060_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/21fbc00f24bc/41589_2022_1060_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/7dcc8eede344/41589_2022_1060_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/ffc9cffe9653/41589_2022_1060_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/224aa7a56027/41589_2022_1060_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/014d9bcd137f/41589_2022_1060_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/c51c5945971b/41589_2022_1060_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/481daa279206/41589_2022_1060_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/9576f3649c88/41589_2022_1060_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/738df6db5a0d/41589_2022_1060_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/cd4d38b0aa69/41589_2022_1060_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/50e5692079af/41589_2022_1060_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/72c432ada69e/41589_2022_1060_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/899ead596b76/41589_2022_1060_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b6/9512702/21fbc00f24bc/41589_2022_1060_Fig13_ESM.jpg

相似文献

1
A dimeric proteomimetic prevents SARS-CoV-2 infection by dimerizing the spike protein.二聚体拟肽通过二聚化刺突蛋白来预防 SARS-CoV-2 感染。
Nat Chem Biol. 2022 Oct;18(10):1046-1055. doi: 10.1038/s41589-022-01060-0. Epub 2022 Jun 2.
2
Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2.冠状病毒刺突蛋白和宿主 ACE2 受体的组成和分化预测了 SARS-CoV-2 的潜在中间宿主。
J Med Virol. 2020 Jun;92(6):595-601. doi: 10.1002/jmv.25726. Epub 2020 Mar 11.
3
Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals.高度保守的 ACE2 结合区域作为人类和哺乳动物之间 SARS-CoV-2 的受体。
Vet Q. 2020 Dec;40(1):243-249. doi: 10.1080/01652176.2020.1823522.
4
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.从头设计皮摩尔级 SARS-CoV-2 小蛋白抑制剂。
Science. 2020 Oct 23;370(6515):426-431. doi: 10.1126/science.abd9909. Epub 2020 Sep 9.
5
Structural basis of receptor recognition by SARS-CoV-2.SARS-CoV-2 受体识别的结构基础。
Nature. 2020 May;581(7807):221-224. doi: 10.1038/s41586-020-2179-y. Epub 2020 Mar 30.
6
Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.SARS-CoV-2 刺突蛋白中与 ACE2 和中和抗体相互作用的受体结合基序的关键残基。
Cell Mol Immunol. 2020 Jun;17(6):621-630. doi: 10.1038/s41423-020-0458-z. Epub 2020 May 15.
7
Structural basis and analysis of hamster ACE2 binding to different SARS-CoV-2 spike RBDs.仓鼠 ACE2 与不同 SARS-CoV-2 刺突 RBD 结合的结构基础和分析。
J Virol. 2024 Mar 19;98(3):e0115723. doi: 10.1128/jvi.01157-23. Epub 2024 Feb 2.
8
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.SARS-CoV-2 刺突受体结合域与 ACE2 受体复合物的结构。
Nature. 2020 May;581(7807):215-220. doi: 10.1038/s41586-020-2180-5. Epub 2020 Mar 30.
9
Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.通过远端多碱性切割位点增强严重急性呼吸综合征冠状病毒2刺突蛋白与受体的结合
ACS Nano. 2020 Aug 25;14(8):10616-10623. doi: 10.1021/acsnano.0c04798. Epub 2020 Aug 4.
10
Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism.SARS-CoV-2 刺突蛋白 RBD 与 ACE2 的相互作用:与 SARS-CoV 的相似性、热点分析及受体多态性的影响。
Biochem Biophys Res Commun. 2020 Jun 30;527(3):702-708. doi: 10.1016/j.bbrc.2020.05.028. Epub 2020 May 14.

引用本文的文献

1
In vivo antibody diversification targeting a conserved coronavirus epitope.针对保守冠状病毒表位的体内抗体多样化
J Exp Med. 2025 Oct 6;222(10). doi: 10.1084/jem.20241563. Epub 2025 Jul 17.
2
Self-assembled proteomimetic (SAP) with antibody-like binding from short PNA-peptide conjugates.具有来自短肽核酸 - 肽缀合物的抗体样结合的自组装拟蛋白质(SAP)。
Proc Natl Acad Sci U S A. 2025 Feb 18;122(7):e2412850122. doi: 10.1073/pnas.2412850122. Epub 2025 Feb 14.
3
Structure-guided engineering of a mutation-tolerant inhibitor peptide against variable SARS-CoV-2 spikes.

本文引用的文献

1
Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants.Delta 和 Kappa SARS-CoV-2 变体中 Spike 蛋白适应性增强的结构和生化基础。
Nat Commun. 2022 Feb 8;13(1):742. doi: 10.1038/s41467-022-28324-6.
2
A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo.一种双特异性单体纳米抗体可诱导刺突三聚体二聚化并在体内中和新冠病毒。
Nat Commun. 2022 Jan 10;13(1):155. doi: 10.1038/s41467-021-27610-z.
3
Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative.
针对可变的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的耐突变抑制剂肽的结构导向工程设计
Proc Natl Acad Sci U S A. 2025 Jan 28;122(4):e2413465122. doi: 10.1073/pnas.2413465122. Epub 2025 Jan 24.
4
Interplay between C Methylation and C Stereochemistry in the Folding Energetics of a Helix-Rich Miniprotein.富含螺旋的微型蛋白质折叠能量学中C甲基化与C立体化学之间的相互作用。
Chembiochem. 2025 Mar 15;26(6):e202401022. doi: 10.1002/cbic.202401022. Epub 2025 Jan 24.
5
Development of DuoMYC: a synthetic cell penetrant miniprotein that efficiently inhibits the oncogenic transcription factor MYC.双MYC的开发:一种能有效抑制致癌转录因子MYC的可穿透细胞的合成微型蛋白质。
Angew Chem Int Ed Engl. 2025 Jan 21;64(4):e202416082. doi: 10.1002/anie.202416082. Epub 2024 Nov 6.
6
Structural understanding of SARS-CoV-2 virus entry to host cells.对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)进入宿主细胞的结构理解。
Front Mol Biosci. 2023 Nov 2;10:1288686. doi: 10.3389/fmolb.2023.1288686. eCollection 2023.
7
Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.基于 ACE2 受体或工程化 Spike 结合肽的 SARS-CoV-2 进入抑制剂比较。
J Virol. 2023 Aug 31;97(8):e0068423. doi: 10.1128/jvi.00684-23. Epub 2023 Aug 9.
8
Advances in developing ACE2 derivatives against SARS-CoV-2.开发针对 SARS-CoV-2 的 ACE2 衍生物的进展。
Lancet Microbe. 2023 May;4(5):e369-e378. doi: 10.1016/S2666-5247(23)00011-3. Epub 2023 Mar 16.
9
Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2.开发针对 SARS-CoV-2 刺突受体结合基序的高效基于 LCB1 的脂肽。
Antiviral Res. 2023 Mar;211:105541. doi: 10.1016/j.antiviral.2023.105541. Epub 2023 Jan 20.
高度耐热、三聚体 SARS-CoV-2 受体结合域衍生物的免疫原性和保护效力。
ACS Infect Dis. 2021 Aug 13;7(8):2546-2564. doi: 10.1021/acsinfecdis.1c00276. Epub 2021 Jul 14.
4
Conformational flexibility and structural variability of SARS-CoV2 S protein.SARS-CoV-2 S 蛋白的构象灵活性和结构变异性。
Structure. 2021 Aug 5;29(8):834-845.e5. doi: 10.1016/j.str.2021.04.006. Epub 2021 Apr 30.
5
A Sos proteomimetic as a pan-Ras inhibitor.一种 Sos 蛋白模拟物作为一种泛 Ras 抑制剂。
Proc Natl Acad Sci U S A. 2021 May 4;118(18). doi: 10.1073/pnas.2101027118.
6
Enhanced Suppression of a Protein-Protein Interaction in Cells Using Small-Molecule Covalent Inhibitors Based on an -Acyl--alkyl Sulfonamide Warhead.基于 -酰基-烷基磺酰胺弹头的小分子共价抑制剂在细胞中增强蛋白质-蛋白质相互作用的抑制作用。
J Am Chem Soc. 2021 Mar 31;143(12):4766-4774. doi: 10.1021/jacs.1c00703. Epub 2021 Mar 18.
7
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
8
Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides.靶向 SARS-CoV-2 刺突蛋白的订书肽 hACE2。
Chem Commun (Camb). 2021 Apr 4;57(26):3283-3286. doi: 10.1039/d0cc08387a. Epub 2021 Mar 2.
9
Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalization.旨在靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的钉合血管紧张素转换酶2(ACE2)拟肽不能阻止病毒内化。
Pept Sci (Hoboken). 2021 Jul;113(4):e24217. doi: 10.1002/pep2.24217. Epub 2021 Jan 8.
10
A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent.一种三聚体人血管紧张素转换酶 2 作为抗 SARS-CoV-2 药物。
Nat Struct Mol Biol. 2021 Feb;28(2):202-209. doi: 10.1038/s41594-020-00549-3. Epub 2021 Jan 11.